Navigation Links
Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
Date:9/17/2007

he world leader in research, development and manufacturing of influenza vaccines, sanofi pasteur is actively involved in several pandemic preparedness projects in the U.S. and Europe, with the goal of developing a vaccine to protect against a pandemic influenza virus. Sanofi pasteur is also investing in major expansions of its seasonal influenza vaccine production facilities in the U.S. and France, which could be used to produce pandemic influenza vaccine if the need arises.

For more information please visit http://pandemic.influenza.com

About sanofi-aventis

Sanofi-aventis is one of the world leaders in the pharmaceutical industry, ranking number one in Europe. Backed by a world-class R&D organisation, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi pasteur, the vaccines division of the sanofi-aventis Group, provided more than a billion doses of vaccine in 2006, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, sanofi pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The Company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR1 million in research and development. For more information, please visit: http://www.sanofipasteur.com or http://www.sanofipasteur.us

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigatio
'/>"/>

SOURCE Sanofi Pasteur
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. New Mexico firm to make flu vaccine at Wisconsin BioManufacturing facility
2. Studies Offer New Insight into HIV Vaccine Development
3. Inacom Information Systems achieves Cisco Systems Partner -Gold Certified status
4. Third Wave Achieves Milestone, Delivers 200,000 SNP Assays to RIKEN In Japan
5. Immune boosting beverage relying on Milwaukee firms packaging technology
6. UW scientist wins Pew grant to study little-known immune cells
7. Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system
8. FLIPR Calcium 3 Assay Kit - An Optimal No-Wash Fluorescence Calcium Indicator Reagent for Non-Optimal Calcium Responses
9. IT critical in pandemic response, but many are not paying attention
10. Quick response manufacturing and biotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 The largest international professional organization of ... therapeutic derivatives thereof has endorsed an educational program ... the challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural ...
(Date:1/14/2014)... Boston, MA (PRWEB) January 14, 2014 iLab ... Michelle Detwiler as the new Director of Product Strategy. In ... as well as iLab sub-teams to guide in the development ... that iLab provides the maximum possible benefit to the scientific ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
(Date:1/14/2014)... 2014   Kinaxis ®, provider of RapidResponse ®, a ... operations planning ( S&OP ) service, is proud to be ... will be held at the Hilton San Diego Bayfront, January ... Elisabeth Kaszas , Director of Supply Chain at Amgen, ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... BALTIMORE, March 24, 2011 Champions Biotechnology, Inc. ... a technology collaboration agreement with Cephalon, Inc. in ... on two proprietary chemical compounds, CEP-32496, an inhibitor ... ALK-FAK inhibitor, provided by Cephalon to determine the ...
... Calif., March 24, 2011 ValGenesis, Inc., an ... solutions, today announced the availability of its industry-proven ... (SaaS) offering hosted on MUSA,s Validated Cloud. ... Lifecycle Management solution accessible via the Internet through ...
... Rules-Based Medicine, Inc. (RBM), a leading provider of innovative ... OncologyMAP ® , a powerful tool developed at the ... Institute. Through quantitative measurement of 101 cancer-related proteins, OncologyMAP ... on biological pathways that could hold the key to ...
Cached Biology Technology:Champions Announces Technology Collaboration Utilizing Champions' Tumorgraft™ Technology Platform for Oncology Drug Development 2Champions Announces Technology Collaboration Utilizing Champions' Tumorgraft™ Technology Platform for Oncology Drug Development 3Announcing ValGenesis On-Demand SaaS Solution 2Announcing ValGenesis On-Demand SaaS Solution 3Rules-Based Medicine Launches OncologyMAP® to Advance Cancer-Related Drug and Diagnostic Development 2
(Date:4/17/2014)... inhibits RSV infection , Respiratory syncytial virus ... tract infections, generating life-threating illness in very young ... are limited. RSV enters host cells through the ... fusogenic bundle. Small interfering peptides that prevent bundle ... peptides are highly susceptible to degradation. In this ...
(Date:4/17/2014)... Professor Marc Andr Gauthier and Professor Luca Razzari ... each been awarded large grants from the John ... for Innovation (CFI) for the acquisition of state-of-the-art ... be added matching grants from the Ministre de ... et de la Technologie (MESRST). These new laboratories ...
(Date:4/17/2014)... marrow need to produce hydrogen sulfide in order to ... new study from the Center for Craniofacial Molecular Biology ... , Professor Songtao Shi, principal investigator on the project, ... cells governs the flow of calcium ions. The essential ... in osteogenesis, or the creation of new bone tissue, ...
Breaking Biology News(10 mins):JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6New state-of-the-art biotech and nanotech equipment for INRS 2
... 16, 2011The American Association for the Advancement of ... Srivastava, MD, a Fellow for his efforts to ... directs cardiac and stem cell research at Gladstone, ... research efforts are focused in the areas of ...
... (OGI) has awarded two research facilities with $10,000 each ... the work of Ontario researchers., ,The two recipients ... The Hospital for Sick Children (SickKids) in Toronto and ... StemCore Laboratories based at the Ottawa Hospital Research Institute. ...
... animal, from a blue whale to a human being, ... the cells in its body will die without reproducing; ... the next generation. How could the extreme degree ... aren,t all creatures unicellular individualists determined to pass on ...
Cached Biology News:Gladstone scientist Deepak Srivastava named fellow of the AAAS 22 research facilities awarded technology seeding grants 2Close family ties keep microbial cheaters in check, study finds 2Close family ties keep microbial cheaters in check, study finds 3Close family ties keep microbial cheaters in check, study finds 4Close family ties keep microbial cheaters in check, study finds 5
... protein assay kit I provides reagents and a ... presence of reducing agents and detergents. The RC ... kit includes reagents and standards sufficient for 500 ... ml RC reagent II, 250 ml alkaline copper ...
5X StabilCoat Immunoassay Stabilizer is a 5X concentrate solution of StabilCoat Immunoassay Stabilizer. The shelf-life of 5X StabilCoat Immunoassay Stabilizer is 2 years when stored at 4C. Product ...
... three-color reagent kit for determining the absolute ... blood samples, mobilized peripheral blood samples, and ... a total nucleated cell count and a ... is designed for use in the BD ...
... Rhodopsin is a glycoprotein which is ... and reptiles. The rhodopsin protein is present ... Immunogen: Membrane preparation from ... This antibody specifically labels the axons andsynaptic ...
Biology Products: